

Rhythm Pharmaceuticals reports two-year Phase 3 setmelanotide data and new expert diagnostic criteria for acquired hypothalamic obesity.
You can purchase shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) through any online brokerage.
Other companies in Rhythm Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Rhythm Pharmaceuticals has a consensus price target of $132.37.
The stock price for Rhythm Pharmaceuticals (NASDAQ: RYTM) is $119 last updated November 18, 2026 at 6:15 PM EST.
There are no upcoming dividends for Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor...